ChemotherapyFDA-approvedFirst-line
Cisplatin
How it works
Damages the DNA of cancer cells, preventing them from reproducing. It also triggers an immune response against cancer cells.
Cancer types
Ovarian Cancer— All patients
Efficacy
Cisplatin has been shown to improve survival in ovarian cancer patients, with a median overall survival of approximately 30 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Chemotherapy Options for Lung Cancer Patients | Lung Cancer | meta-analysis | — | Source → |
| Cancer Cells' Metabolism Changes When Resistant to Cisplatin | Lung Cancer | lab-study | — | Source → |
| Testing Sacituzumab Govitecan and Cisplatin in Ovarian and Endometrial Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Artemisia Extract May Enhance Lung Cancer Treatment | Lung Cancer | lab-study | The combination treatment showed a greater cytotoxic effect than either treatment alone, with a combination index (CI) of 0.7. | Source → |
| PKM2 Inhibitors May Help Treat Cisplatin-Resistant Ovarian Cancer | Ovarian Cancer | lab-study | Combination therapy with high-dose PKM2 inhibitors and cisplatin increased apoptosis compared to controls, although the modest induction suggests apoptosis is only partially responsible for the observed effects. | Source → |
| HDAC2 Linked to Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| JMJD5 protein may help chemotherapy work better in lung cancer | Lung Cancer | lab-study | — | Source → |
| Cisplatin May Weaken Lung Cancer Immune Response | Lung Cancer | lab-study | Pretreatment with GW4869, an exosome release inhibitor, significantly enhanced cisplatin sensitivity in HCC827 cells. | Source → |
| Comparing Chemotherapy Options for Lung Cancer Patients | Lung Cancer | observational | Five-year overall survival and recurrence-free survival numerically favored cisplatin (61.0% vs 48.8%, P=0.17; 63.9% vs 56.6%, P=0.12). | Source → |
| New Treatment Combination Shows Promise for Lung Cancer | Lung Cancer | lab-study | — | Source → |
| New Biomarkers for Lung Cancer Treatment Identified | Lung Cancer | lab-study | — | Source → |
| Understanding Resistance to Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| Comparing Carboplatin and Cisplatin in Lung Cancer Treatment | Lung Cancer | meta-analysis | — | Source → |
| Ginsenoside Rg3 Enhances Cancer Treatment with Cisplatin | Lung Cancer | lab-study | — | Source → |
| USP19 and DnaJC7 May Help Cancer Treatment Work Better | Ovarian Cancer | lab-study | — | Source → |
| Cancer Researchers Study Re-Challenging a Patient with Platinum-Based Chemotherapy | Lung Cancer | observational | — | Source → |
| TRIM33 May Help Overcome Lung Cancer Resistance to Cisplatin | Lung Cancer | lab-study | — | Source → |
| Gemcitabine and Cisplatin with or without Veliparib for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Diosmetin Enhances Effectiveness of Cancer Treatment in Lab Experiments | Ovarian Cancer | lab-study | — | Source → |
| Testing Combination Therapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Researchers Identify New Player in Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Cancer Research Uncovers New Pathway for Cisplatin Resistance | Lung Cancer | lab-study | — | Source → |
| Cancer Cells May Resist Treatment Due to Body's Internal Clock | Lung Cancer | lab-study | — | Source → |
| Cisplatin May Weaken Cancer Treatment by Boosting Immune Suppression | Ovarian Cancer | lab-study | — | Source → |
| MicroRNA Linked to Breast Cancer Resistance to Chemotherapy | Breast Cancer | lab-study | — | Source → |
| Understanding Cisplatin Resistance in Small Cell Lung Cancer | Lung Cancer | review | — | Source → |
| Testing Cisplatin and Radiation Therapy in Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Researchers Identify New Target to Overcome Cisplatin Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Geniposide Enhances Cisplatin Sensitivity in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Link between gene modification and chemotherapy resistance in ovarian cancer | Ovarian Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells May Resist Treatment by Producing a Specific DNA Fragment | Ovarian Cancer | lab-study | Cisplatin showed limited efficacy in reducing tumor growth in resistant tumors. | Source → |
| Neutrophil Traps Contribute to Ovarian Cancer Resistance to Platinum | Ovarian Cancer | lab-study | — | Source → |
| Combining Cisplatin and Sulforaphane May Improve Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Tripterygium Glycosides May Help Overcome Chemotherapy Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Gene Linked to Ovarian Cancer Resistance to Chemotherapy | Ovarian Cancer | lab-study | The diagnostic potential of was moderate, with an area under the curve (AUC) of 0.792. | Source → |
| Researchers Investigate Role of HMGB1 in Overcoming Cisplatin Resistance | Ovarian Cancer | lab-study | — | Source → |
| Cancer Cells May Resist Treatment with Help from Surrounding Cells | Lung Cancer | lab-study | — | Source → |
| Combining Plumbagin and Cisplatin May Help Treat Leukemia | Leukemia | lab-study | Leukemic cells treated with cisplatin/PLB (3 μM/0.4 μM) for 24 h showed markedly reduced viability (45.51%) compared to cisplatin or PLB (81.07% or 76.36%). | Source → |
| USP18 Plays a Role in Ovarian Cancer Cells' Resistance to Cisplatin | Ovarian Cancer | lab-study | — | Source → |
| Gene Pair Linked to Chemotherapy Response in Ovarian Cancer | Ovarian Cancer | lab-study | The ETV4-CIC gene pair achieved the highest predictive performance for cisplatin response in ovarian cancer with an area-under-curve of 0.939. | Source → |
| Cisplatin Treatment May Improve Lung Cancer Outcomes | Lung Cancer | lab-study | The disease control rate in the 24 h retention group was 92.9%, significantly higher than that in the 6 h group (92.7%) and the 1 h group (80.9%). | Source → |
| New Compounds Show Promise in Fighting Lung Cancer | Lung Cancer | lab-study | The benzoxazole derivatives 1a and 1b exhibited anticancer activity against A549 cells, with half-maximal inhibitory concentration (IC) values of 17.41±0.16 and 20.50±0.08 µM, respectively. | Source → |
| ULK2 may help ovarian cancer patients respond better to chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| Using Sodium Thiosulfate to Prevent Kidney Damage in Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Monitoring Body Weight During Cisplatin Chemotherapy | Lung Cancer | observational | — | Source → |
| Macrophage Exosomes Contribute to Lung Cancer Resistance to Cisplatin | Lung Cancer | lab-study | — | Source → |
| New Tool Helps Cancer Cells Absorb Chemotherapy | Ovarian Cancer | lab-study | In vivo, DR-A2 significantly boosted the antitumor efficacy of cisplatin. | Source → |
| Fruit Extract from Sausage Tree Shows Anticancer Activity in Lab Experiments | Colorectal Cancer | lab-study | — | Source → |
| Evodiamine May Help Overcome Lung Cancer Resistance to Cisplatin | Lung Cancer | lab-study | The IC-50 for A549 cells was 4 µM, and for A549 cisplatin-resistant cells, it was 2 µM. | Source → |
| New Lung Cancer Treatment Combination Shows Promise | Lung Cancer | phase-2 | The 2-year survival rate was 88.1%, with a 3-year survival rate of 82.9%. | Source → |
| PD-L1 Upregulation Linked to Poor Prognosis in Ovarian Cancer | Ovarian Cancer | observational | — | Source → |
| Guiqi Yiyuan Ointment May Improve Cancer Treatment | Lung Cancer | animal-study | — | Source → |
| Cancer Cells Develop Resistance to Cisplatin | Lung Cancer | lab-study | Targeting FA metabolism with CPT1A inhibitors or CD36 antagonists, or blocking PARP activity, significantly reversed SART3-mediated resistance. | Source → |
| Researchers Explore New Use for Old Cancer Therapy | Ovarian Cancer | lab-study | — | Source → |
| Wenxia Formula Extract May Help Overcome Lung Cancer Resistance to Cisplatin | Lung Cancer | animal-study | — | Source → |
| Hydrogels May Not Improve Cisplatin's Effectiveness in Breast Cancer | Breast Cancer | meta-analysis | — | Source → |
| Combining Traditional Chinese Medicine with Cisplatin May Help Overcome Ovarian Cancer Resistance | Ovarian Cancer | lab-study | — | Source → |
| GJB2 protein linked to ovarian cancer resistance to chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| HO-1 Depletion May Help Overcome Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Desensitizing Patients to Cisplatin for Ovarian Cancer Treatment | Ovarian Cancer | observational | — | Source → |
| ELK3's Role in Ovarian Cancer Resistance to Cisplatin | Ovarian Cancer | lab-study | — | Source → |
| Combining Cisplatin with GSK2606414 May Help Overcome Ovarian Cancer Resistance | Ovarian Cancer | lab-study | — | Source → |
| Anatolian Propolis May Help Fight Ovarian Cancer | Ovarian Cancer | lab-study | The IC value of propolis was determined as 0.342 ± 0.180 mg/mL in the A2780 cell line. | Source → |
| New Compound May Help Overcome Lung Cancer Resistance to Cisplatin | Lung Cancer | lab-study | — | Source → |
| Combining Temozolomide and Cisplatin in Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Combining Chemotherapy Drugs Boosts Immune Response in Cancer | Colorectal Cancer | lab-study | — | Source → |
| MMP3's Role in Ovarian Cancer Resistance to Cisplatin | Ovarian Cancer | lab-study | siRNA-mediated MMP3 knockdown significantly reduced viability, proliferation, and invasion, and these effects were further enhanced when combined with cisplatin treatment. | Source → |
| KDM4A Gene Silencing May Help Overcome Chemotherapy Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Oleanolic Acid and Cisplatin to Treat Pancreatic Cancer | Pancreatic Cancer | lab-study | The output of analysis of the anti-proliferative and cytotoxicity effect of OA and CIS tends to show the significant inhibition of cells in a dose-dependent manner with IC value of 5.75 μM OA and 2.95 μM of CIS. | Source → |
| Gene Linked to Chemotherapy Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Insight into Ovarian Cancer Resistance to Treatment | Ovarian Cancer | lab-study | — | Source → |
| Combining Quercetin and Cisplatin May Improve Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| PARP Inhibitors May Help Lung Cancer Patients Respond Better to Chemotherapy | Lung Cancer | lab-study | — | Source → |
| Lung Cancer Cells May Adapt to Chemotherapy | Lung Cancer | lab-study | — | Source → |
| Combining silica nanoparticles, cisplatin, and quercetin may help treat ovarian cancer | Ovarian Cancer | animal-study | — | Source → |
| Ovarian Cancer Cells' Response to Cisplatin May Be Influenced by AUF1 Protein | Ovarian Cancer | lab-study | — | Source → |
| Combining aripiprazole with cisplatin may help treat pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| Propofol May Enhance Effectiveness of Ovarian Cancer Treatments | Ovarian Cancer | lab-study | — | Source → |
| New Study Compares Treatments for Rare Ovarian Tumors | Ovarian Cancer | phase-2 | Median progression-free survival was 27.7 months for paclitaxel and carboplatin, and 19.7 months for bleomycin, etoposide, and cisplatin. | Source → |
| Ovarian Cancer Biomarker Identified in Lab Study | Ovarian Cancer | lab-study | — | Source → |
| Cancer Research: METTL3 and circ_0000620's Role in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Combining Metformin with Cisplatin May Reduce Effectiveness in Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Link between MUL1 gene and ovarian cancer resistance to cisplatin identified | Ovarian Cancer | lab-study | Platinum resistance increased with the upregulation of MUL1 expression (Cor = 0.5154, P = 0.02). | Source → |
| New Targets for Overcoming Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Gene Study Identifies New Targets for Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Long Noncoding RNA Linked to Cisplatin Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Researchers Identify Genes Linked to Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Way to Deliver Cancer Medicine to Colon Cancer Cells | Colorectal Cancer | lab-study | The organoselenium compound significantly improved cisplatin loading efficiency within the liposomes (83.4%). | Source → |
| Gene Linked to Lung Cancer Resistance to Cisplatin Identified | Lung Cancer | lab-study | — | Source → |
| TGF-β1 and ISG20 Role in Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Cancer Gene c-Myb Linked to Resistance to Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Evodiamine Helps Overcome Cisplatin Resistance in Lung Cancer Cells | Lung Cancer | lab-study | — | Source → |
| MicroRNAs Linked to Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | Targeting these microRNAs with oligonucleotide miRNA inhibitors reduced proliferation by more than 50% for several microRNAs. | Source → |
| Dihydroartemisinin Enhances Cisplatin's Effect on Lung Cancer Cells | Lung Cancer | lab-study | — | Source → |
| USP3 linked to lung cancer resistance to cisplatin | Lung Cancer | lab-study | — | Source → |
| New Cancer-Fighting Compound Shows Promise Against Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining two drugs may help overcome lung cancer resistance | Lung Cancer | lab-study | — | Source → |
| Adjuvant Therapy May Help Some Lung Cancer Patients | Lung Cancer | observational | The 5-year overall survival rate was 76.1% in patients who received adjuvant therapy, compared to 50.0% in those who did not. | Source → |
| Cisplatin's Effect on Cancer Cells Not Affected by Short-Term Autophagy Inhibition | Prostate Cancer | lab-study | — | Source → |
| MicroRNA-486-5p May Help Overcome Cisplatin Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells Show Resistance to Platinum-Based Chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| BIRC5 plays a role in ovarian cancer resistance to chemotherapy | Ovarian Cancer | lab-study | Tumors were significantly smaller in size and volume when BIRC5 was silenced. | Source → |
| MicroRNA May Help Lung Cancer Cells Respond Better to Chemotherapy | Lung Cancer | lab-study | — | Source → |
| Targeted Chemotherapy Delivery for Cancer Treatment | Melanoma | lab-study | At the same concentration in solution, the complex was as effective as cisPt alone. | Source → |
| Quinacrine Enhances Cisplatin's Anti-Cancer Effectiveness | Colorectal Cancer | lab-study | — | Source → |
| TMED2 Linked to Cisplatin Resistance in Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Cancer Treatment Combination Tested in Ovarian Cancer Patients | Ovarian Cancer | phase-1 | — | Source → |
| LDLR's Role in Ovarian Cancer Resistance to Cisplatin | Ovarian Cancer | lab-study | — | Source → |
| New Nanodrug Delivery System May Help Overcome Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining selamectin with cisplatin may improve uveal melanoma treatment | Melanoma | lab-study | — | Source → |
| Costunolide Sensitizes Ovarian Cancer Cells to Cisplatin | Ovarian Cancer | lab-study | — | Source → |
| m6A Modification Helps Overcome Cisplatin Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Targeted Nanoparticles Help Treat Cisplatin-Resistant Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Cisplatin and Vinorelbine May Help Some Ovarian Cancer Patients | Ovarian Cancer | observational | The objective response rate was 18.8% and the disease control rate was 75.1%. | Source → |
| Combining Light Therapy and Chemotherapy May Help Treat Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Cancer Cells React Differently to Different Cisplatin Doses | Colorectal Cancer | lab-study | — | Source → |
| New Nanocarriers Deliver Cancer Drugs More Effectively | Breast Cancer | lab-study | Nio-Cis-Dox-AL showed appropriate encapsulation efficiencies of 65.54 ± 1.25% and 80.65 ± 1.80% for Cis and Dox, respectively. | Source → |
| Heat Therapy and Chemotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-3 | Median post-recurrence survival was significantly prolonged in the GPH-group (15.3 versus 9.8 months; p = 0.031). | Source → |
| Anlotinib Shows Promise Against Resistant Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Delivery System for Cancer Treatment Shows Promise | Ovarian Cancer | lab-study | The combination of cisplatin and silibinin-NLCs sensitized the cisplatin-resistant A2780 OC cells and exhibited a more synergistic inhibitory effect on A2780 cells as compared with the combination of cisplatin and plain silibinin. | Source → |
| Wentilactone A May Help Overcome Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells May Resist Treatment Due to a Specific Gene | Ovarian Cancer | lab-study | — | Source → |
| New Nanoparticles May Help Treat Cisplatin-Resistant Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Anaphylactic Reaction to Carboplatin Diagnosed by Skin Testing | Ovarian Cancer | observational | — | Source → |
| New Compounds Show Promise in Fighting Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Cancer Cells May Develop Resistance to Treatment by Increasing PD-L1 Expression | Lung Cancer | lab-study | — | Source → |
| USP22 linked to pancreatic cancer cell resistance to treatment | Pancreatic Cancer | lab-study | — | Source → |
| p62 Protein Affects How Cancer Cells Respond to Chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| Overcoming Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | review | — | Source → |
| Circular RNA may contribute to ovarian cancer resistance to chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| Pleiotrophin may affect how prostate cancer cells respond to a common chemotherapy drug | Prostate Cancer | lab-study | — | Source → |
| Combining Peptide and Chemotherapy Shows Promise in Lung Cancer | Lung Cancer | lab-study | The combination of 37.5 μM of CIGB-552 and 5 μM of CDDP achieved a clear synergic effect on proliferation inhibition, cell cycle arrest, apoptosis induction, and oxidative stress response. | Source → |
| IRF-1's Role in Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Comparing Chemotherapy Treatments for Esophageal Cancer | Lung Cancer | phase-2 | The overall response rate in the taxane-based group was higher than the non-taxane-based group, but was not significantly different (p=0.851). | Source → |
| Cisplatin Boosts Immune Response in Triple-Negative Breast Cancer | Breast Cancer | animal-study | — | Source → |
| Cancer Cells' Resistance to Chemotherapy Drug Studied | Ovarian Cancer | lab-study | — | Source → |
| CircRNA_101277 May Contribute to Colorectal Cancer Resistance to Chemotherapy | Colorectal Cancer | lab-study | — | Source → |
| Combination Therapy for Esophageal Cancer Shows Promise | Leukemia | phase-3 | The total treatment efficiency in the study group was 86%. | Source → |
| Researchers Test a Virus to Target Mesothelioma Cells | Lung Cancer | lab-study | — | Source → |
| MicroRNA May Help Overcome Cisplatin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify Potential Target for Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Rare Cancer Patient Shows Complete Response to Chemotherapy | Pancreatic Cancer | observational | — | Source → |
| MicroRNAs may play a role in ovarian cancer treatment resistance | Ovarian Cancer | review | — | Source → |
| Cancer Cells' Response to Chemotherapy May Be Influenced by SIRT3 | Breast Cancer | lab-study | — | Source → |
| New Compound May Help Cancer Cells Respond Better to Treatment | Melanoma | lab-study | — | Source → |
| Hydrogel Helps Deliver Cancer Drug to Ovarian Cancer Cells | Ovarian Cancer | lab-study | — | Source → |
| New Antibody Shows Promise Against Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells' Response to Cisplatin Treatment | Ovarian Cancer | lab-study | — | Source → |
| Combining Medications May Help Overcome Ovarian Cancer Resistance | Ovarian Cancer | lab-study | — | Source → |
| FGFR3 linked to ovarian cancer resistance to chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| PGC1α May Contribute to Ovarian Cancer Resistance to Cisplatin | Ovarian Cancer | lab-study | — | Source → |
| New Chemotherapy Combination Shows Promise for Ovarian Clear Cell Carcinoma | Ovarian Cancer | phase-1 | Two evaluable patients showed a partial response. | Source → |
| Curcumin Sensitizes Lung Cancer Stem Cells to Cisplatin | Lung Cancer | lab-study | Curcumin significantly suppressed colonies formation by 50%. | Source → |
| Combining two treatments may help fight lung cancer | Lung Cancer | lab-study | The combination of PD-0332991 and cisplatin increased apoptosis to 7.06% in A549 cells and 7.03% in A549/CDDP cells, and G0/G1 cell cycle arrest to 9.15% in A549 cells and 49.92% in A549/CDDP cells. | Source → |
| Long non-coding RNA linked to lung cancer resistance | Lung Cancer | lab-study | — | Source → |
| New Compounds Enhance Effectiveness of Platinum-Based Cancer Drugs | Lung Cancer | lab-study | — | Source → |
| FSTL1 Protein May Help Ovarian Cancer Cells Respond to Treatment | Ovarian Cancer | lab-study | The IC50 of cells treated with different concentrations of DDP was decreased after over-expressing FSTL1. | Source → |
| Link Between Enzyme and Lung Cancer Stem Cell Resistance to Chemotherapy | Lung Cancer | lab-study | — | Source → |
| New Compound May Help Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| How Two Cancer Drugs Affect Cells Differently | Lung Cancer | lab-study | — | Source → |
| LncRNA XIST May Help Predict Lung Cancer Resistance to Cisplatin | Lung Cancer | lab-study | — | Source → |
| MicroRNAs and Lung Cancer: A Complex Role in Chemotherapy | Lung Cancer | review | — | Source → |
| New Target for Lung Cancer Treatment Identified | Lung Cancer | lab-study | — | Source → |
| GLUT10's Role in Breast Cancer and Cisplatin Resistance | Breast Cancer | lab-study | The shSLC2A10#1 and shSLC2A10#2 groups exhibited increased intracellular ROS levels (relative fluorescence intensity: 1.78±0.12 and 2.05±0.15, respectively; ＜0.05), increased cisplatin sensitivity, reduced colony numbers, and promoted cisplatin-induced ROS accumulation and apoptosis. | Source → |
| Low-dose dihydroartemisinin may improve lung cancer treatment | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.